Literature DB >> 22634621

α-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells.

Eyal Ozeri1, Mark Mizrahi, Galit Shahaf, Eli C Lewis.   

Abstract

Tolerogenic IL-10-positive CCR7-positive dendritic cells (DC) promote T regulatory (Treg) cell differentiation upon CCR7-dependent migration to draining lymph nodes (DLN). Indeed, in human DC deficiencies, Treg levels are low. α-1 antitrypsin (AAT) has been shown to reduce inflammatory markers, promote a semimature LPS-induced DC phenotype, facilitate Treg expansion, and protect pancreatic islets from alloimmune and autoimmune responses in mice. However, the mechanism behind these activities of AAT is poorly understood. In this study, we examine interactions among DC, CD4(+) T cells, and AAT in vitro and in vivo. IL-1β/IFN-γ-mediated DC maturation and effect on Treg development were examined using OT-II cells and human AAT (0.5 mg/ml). CCL19/21-dependent migration of isolated DC and resident islet DC was assessed, and CCR7 surface levels were examined. Migration toward DLN was evaluated by FITC skin painting, transgenic GFP skin tissue grafting, and footpad DC injection. AAT-treated stimulated DC displayed reduced MHC class II, CD40, CD86, and IL-6, but produced more IL-10 and maintained inducible CCR7. Upon exposure of CD4(+) T cells to OVA-loaded AAT-treated DC, 2.7-fold more Foxp3(+) Treg cells were obtained. AAT-treated cells displayed enhanced chemokine-dependent migration and low surface CD40. Under AAT treatment (60 mg/kg), DLN contained twice more fluorescence after FITC skin painting and twice more donor DC after footpad injection, whereas migrating DC expressed less CD40, MHC class II, and CD86. Intracellular DC IL-10 was 2-fold higher in the AAT group. Taken together, these results suggest that inducible functional CCR7 is maintained during AAT-mediated anti-inflammatory conditions. Further studies are required to elucidate the mechanism behind the favorable tolerogenic activities of AAT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634621     DOI: 10.4049/jimmunol.1101340

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Immune-modulating effects of alpha-1 antitrypsin.

Authors:  Mario R Ehlers
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

2.  Regulatory and Exhausted T Cell Responses to AAV Capsid.

Authors:  Gwladys Gernoux; James M Wilson; Christian Mueller
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

3.  Human α1-antitrypsin modifies B-lymphocyte responses during allograft transplantation.

Authors:  Mark Mizrahi; Pablo Cal; Martin Rosenthal; David Ochayon; Galit Shahaf; Ziv Kaner; Peter Kachker; Eli C Lewis
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

4.  Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells.

Authors:  Yuchun Luo; Xiangna Cai; Sucai Liu; Sen Wang; Claudia A Nold-Petry; Marcel F Nold; Philip Bufler; David Norris; Charles A Dinarello; Mayumi Fujita
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-07       Impact factor: 11.205

5.  Enhanced Survival and Accelerated Perfusion of Skin Flap to Recipient Site Following Administration of Human α1-Antitrypsin in Murine Models.

Authors:  Ronen Schuster; Or Bar-Nathan; Alon Tiosano; Eli C Lewis; Eldad Silberstein
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-07-02       Impact factor: 4.730

Review 6.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

Review 7.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

8.  α1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation.

Authors:  Avishag Abecassis; Ronen Schuster; Galit Shahaf; Eyal Ozeri; Ross Green; David E Ochayon; Peleg Rider; Eli C Lewis
Journal:  Cell Mol Immunol       Date:  2014-04-07       Impact factor: 11.530

9.  α1-Antitrypsin modifies general NK cell interactions with dendritic cells and specific interactions with islet β-cells in favor of protection from autoimmune diabetes.

Authors:  Ofer Guttman; Rami Yossef; Gabriella Freixo-Lima; Peleg Rider; Angel Porgador; Eli C Lewis
Journal:  Immunology       Date:  2014-10-13       Impact factor: 7.397

10.  α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics.

Authors:  A Mario Marcondes; Ekapun Karoopongse; Marina Lesnikova; Daciana Margineantu; Tobias Welte; Charles A Dinarello; David Hockenbery; Sabina Janciauskiene; H Joachim Deeg
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.